

010008E1.APP
SEQUENCE LISTING

<110> Aventis Pharma Deutschland GmbH
<120> Use of fusion proteins whose N-terminal part is a
hirudin derivative for the production of recombinant
proteins via secretion by yeasts
<130> DEAV2001/0008
<140> 10108211.8
<141> 2001-02-20
<160> 11
<170> PatentIn Ver. 2.1
<210> 1
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:hir_insf1

<400> 1
atccctgagg aataccttca gcgatttggt aaccaacact tgtgtgg

47

<210> 2
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:protein
hir_insf1

<400> 2
Ile Pro Glu Glu Tyr Leu Gln Arg Phe Val Asn Gln His Leu Cys
1 5 10 15

<210> 3
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: hir_insf1

<400> 3
cctcacaagt gttggttaac aaatcgctga aggtattcct cagggat

47

<210> 4
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: hirf1

10075532.021902

<400> 4
 tttttttgga tccttttgat aaaagactta cgtatactga ctgcac

46

<210> 5
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: protein hirf1

<400> 5
 Leu Thr Tyr Thr Asp Cys
 1 5

<210> 6
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: insncolrev

<400> 6
 ttttttccat gggtcgacta tcag

24

<210> 7
 <211> 59
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Hir_insf

<400> 7
 atccctgagg aataccttca gggaaattcg gcacgatttg ttaaccaaca cttgtgtgg 59

<210> 8
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: protein
 Hir_insf

<400> 8
 Gly Asn Ser Ala Arg Phe Val Asn Gln His Leu Cys
 1 5 10

<210> 9
 <211> 59
 <212> DNA
 <213> Artificial Sequence



<400> 9

<400> 10

<400> 11

10769